SCHEMBL29782821

SCHEMBL29782821

CN(C)c1c(C(N)=O)oc2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.55
ALDH1A1 P00352 3/20 0.49
TEAD1 P28347 1/20 0.48
YAP1 P46937 1/20 0.48
TEAD4 Q15561 1/20 0.48
TEAD2 Q15562 1/20 0.48
KDM4E B2RXH2 5/20 0.46
MAPT P10636 4/20 0.45
MAPK10 P53779 4/20 0.45
TP53 P04637 3/20 0.45
HSD17B10 Q99714 3/20 0.45
TSHR P16473 3/20 0.45
AHR P35869 2/20 0.45
KMT2A Q03164 4/20 0.44
MEN1 O00255 2/20 0.44
NPC1 O15118 2/20 0.44
HPGD P15428 3/20 0.44
HTT P42858 1/20 0.44
POLB P06746 1/20 0.44
PKM P14618 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28679305 0.84 ALDH1A1 (0.48) GAAALDH1A1TEAD1YAP1TEAD4
SCHEMBL15714291 0.82 KDM4E (0.65) GAAALDH1A1KDM4EMAPTTP53
SCHEMBL353910 0.77 KCNH2 (0.58) ALDH1A1TEAD1YAP1TEAD4TEAD2
SCHEMBL7574372 0.77 CAPN1 (0.54) ALDH1A1TEAD1YAP1TEAD4TEAD2
SCHEMBL6419143 0.76 HDAC3 (0.50) GAAALDH1A1TEAD1YAP1TEAD4
SCHEMBL650804 0.75 ALDH1A1 (0.54) ALDH1A1TEAD1YAP1TEAD4TEAD2
SCHEMBL1006030 0.75 MAPT (0.67) GAAALDH1A1TEAD1YAP1TEAD4
SCHEMBL15155615 0.75 ALDH1A1 (0.54) ALDH1A1TEAD1YAP1TEAD4TEAD2
SCHEMBL15380938 0.74 ALDH1A1 (0.53) ALDH1A1TEAD1YAP1TEAD4TEAD2
SCHEMBL6382634 0.74 ALDH1A1 (0.53) ALDH1A1TEAD1YAP1TEAD4TEAD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12357603-B2 Acyl sulfonamides for treating cancer BAYER AKTIENGESELLSCHAFT (DE) 2025-07-15 US disclosed
US-20220226279-A1 ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. 2022-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220226279-A1 ACYL SULFONAMIDES FOR TREATING CANCER KAT6A, KAT6B, KAT2A GAA 1486/4885ALDH1A1 1645/4885TEAD1 1214/4885
US-12357603-B2 Acyl sulfonamides for treating cancer KAT6A, KAT6B, KAT2A GAA 1486/4885ALDH1A1 1645/4885TEAD1 1214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.